Media coverage about Merus (NASDAQ:MRUS) has been trending positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merus earned a daily sentiment score of 0.30 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.9133488783898 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
MRUS has been the topic of a number of recent research reports. Wedbush reissued an “outperform” rating and issued a $32.00 target price on shares of Merus in a report on Friday, January 12th. BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a report on Saturday, December 30th. ValuEngine raised Merus from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Finally, Royal Bank of Canada downgraded Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 target price on the stock. in a report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $30.00.
NASDAQ MRUS opened at $16.91 on Friday. Merus has a 52 week low of $13.23 and a 52 week high of $23.75. The stock has a market capitalization of $327.92, a PE ratio of -7.23 and a beta of 0.08.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/merus-mrus-getting-positive-news-coverage-report-shows.html.
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.